Lidocaine, an anti-arrhythmic drug, was quantitated in serum by a commercially supplied enzyme immunoassay procedure. Replicate analyses of serum controls resulted in a within-assay coefficient of variation of 5.0 and a between-assay coefficient of variation of 6.5. Regression analysis of 87 serum samples analyzed by this technique (y) and by gas-liquid chromatography (x) gave the equation y = 0.96x -0.03 (r = 0.99). Clinical evaluation of the results indicates the enzyme immunoassay technique to be highly specific and sensitive for lidocaine.
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EMITpotential pharmacokinetic use
Lidocaine is one of the most widely used drugs in the acute management of cardiac arrhythmias (1, 2) . In the past, dosage regimens for lidocaine were developed empirically;
however, a more recent understanding of the pharmacology and pharmacokinetics of lidocaine has led to the design of more effective therapeutic regimens (2) (3) (4) (5) (6) . To implement these new approaches, it is essential that the laboratory provide clinicians with accurate and timely analytical monitoring of the lidocaine concentration in serum.
Gas-liquid chromatography and high-performance liquid chromatography are currently the two method9 most widely used for measuring drugs and their metabolites (7) (8) (9) (10, 11) .
A homogeneous enzyme immunoassay (EMIT) for the quantitation of lidocaine in serum has become available from Syva Corp., Palo Alto, Calif. 94304 (12) . We evaluated this new procedure and compared it with a gas-liquid chromatographic method.
Materials and Methods

Enzyme Immunoassay
Apparatus.
We used a semi-automated system as recom- mended by Syva Corporation. It consisted of a Model 300-N microsample spectrophotometer equipped with a thermally regulated flowcell set at 30 #{176}C (Gilford Instrument Laboratories, Inc., Oberlin, Ohio 44074), and a Monroe 1305calcu-lator that was modified to function as an EMIT printer-calculator and a pipettor-dilutor, both supplied by Syva Corporation.
Reagents.
The reagents, calibrators (1, 2, 3, 5, and 12 mg/liter), and controls ("low" and "high") were those commercially available from Syva Corporation (12) .
Procedure.
The EMIT lidocaine procedure as established by Syva Corporation was followed (13).
Gas-Liquid Chromatography (by a Modification of
7)
We used an instrument equipped with a flame-ionization detector. The glass column, 155 cm X 2 mm (i.d.), was packed with 2.5% by weight SE-30 on 100/120 mesh Gas Chrom Q (Applied Science Labs, State College, Pa. 16801). The flow rate for the nitrogen carrier gas was 30 ml! mm. The column temperature was programmed from 170 to 250 #{176}C, at a rate of 15 #{176}C/min.
Reagents.
A control was prepared in our laboratory by adding lidocaine to a serum pool.
Procedure.
As an internal standard, add 1.0 ml of an 11.5 mg/liter aqueous solution of mepivacaine hydrochloride to 2.0 ml of either standard or unknown and make the solution alkaline with 1.0 ml of ammonium chloride/ammonium hydroxide buffer (adjust saturated solution of ammonium chloride to pH 9.3 with concentrated ammonium hydroxide). Extract the aqueous solution with diethyl ether and then extract the ether phase with 5 ml of 0.25 mol,'liter sulfuric acid.
Remove the ether phase and make the aqueous phase RlkRline with 0.2 ml of 12 mol/liter sodium hydroxide and 1 ml of ammonium chloride!ammonium hydroxide buffer (pH 9.3).
Re-extract with chloroform, evaporate the chloroform, redissolve the residue in 25 Ml of chloroform, and analyze a 3-Ml aliquot by gas-liquid chromatography.
The retention index (14) for lidocaine and mepivacaine vs.
n-paraffins (C10 to C30) was 1860 and 2075, respectively.
Lidocaine and its N-dealkylated metabolite, monoethylglycinexylidide, were resolved and serum co-extractables were not observed to interfere with this procedure.
immunochemical Selectivity
Reagents. Lidocaine aqueous standard
(1 X 10 mol!liter) was prepared from the hydrocholoride salt; aqueous standards Procedure. The drug standards were analyzed by the same immunoassay procedure as serum samples. Distilled water gave results comparable to those with use of the EMIT buffer solution or drug-free serum, so it was used as the negative in the lidocaine assay. If a non-lidocaine drug showed no cross reactivity in the lidocaine assay-(other drug)gfl <0.1 mg/liter-the molar selectivity ratio was expressed as >2300. Table 1 summarizes the results from the within-assay and between-assay precision studies. The manufacturer states that the EMIT lidocaine assay is designed to quantitate lidocaine concentrations of 1 to 12 mg/liter with a between-assay coefficient of variation <10%; however, our data and studies by Syva Corporation (15) suggest that a much lower CV can be attained.
Results
We evaluated the specificity and sensitivity of the immunoassay by analyzing 26 samples from patients receiving Further to define the selectivity of the immunoassay for lidocaine, we tested 43 other drugs in the lidocaine assay for their potential cross reactivity. Table 2 lists 36 of them that showed no cross reactivity. The molar selectivity ratios for the other seven drugs that are structural analogs of lidocaine are given in Table 3 .
None of the drug standards showed less reactivity (A) in the immunoassay than the negative calibrator, which could have occurred had the drug inhibited the reagent system. The selectivity for lidocaine in comparison to its metabolite, monoethylglycinexylidide, was not determined. Data from Syva Corporation suggest a molar selectivity ratio for lidocaine vs. its metabolite of >30 (13) . The manufacturer has added the metabolite to the immunoassay reagents to absorb any cross-reacting antibodies that might be present. Thus the drugs that showed the greatest cross reactivity, the N-dealkylated metabolite of lidocaine and mepivacaine, would not significantly interfere, even at high therapeutic dosages.
The lidocaine aqueous standard was prepared to have a concentration of 2.34 mg/liter. When the standard was measured in the immunoassay with use of a standard curve prepared with serum calibrators, the lidocaine concentration was 2.35 mg/liter. Thus, the percent recovery was calculated to be 100%.
To compare the immunoassay and gas-liquid chromatographic procedures, we analyzed 87 serum samples that contained lidocaine by both methods. Regression analysis of the data ( Figure 1 ) for immunoassay (x) vs. gas-liquid chromatography (y) gave the following results: y-intercept = 0.03, slope = 0.96, r = 0.99, and standard error of the estimate = 0.32. These results suggest that the immunoassay isrelatively free of systematic errors. Significant cross reactivity with monoethylglycinexylidide would have produced a proportional error; however, the slope of the regression line indicates the absence of such an error.
Ten serum samples containing known concentrations of lidocaine were analyzed by both immunoassay and gas-liquid chromatography. Table 4 lists the calculated concentrations and experimentally determined concentrations for these samples. Analytical recovery by immunoassay averaged 105% (range, 98-116%); that by gas-liquid chromatography averaged 103% (range, 92-112%). Comparison of the two methods for these 10 samples gave r > 0.99.
Discussion
Measurement of the lidocaine concentration in serum is frequently necessary in the acute management of cardiac arrhythmias.
Many factors, such as the unpredictability of (16) . The excellent correlation between results by immunoassay and gas-liquid chromatography, in which both free and bound lidocaine are extracted, suggests that the EMIT assay measures the total lidocaine concentration in serum.
Two potential applications of this enzyme immunoassay are the pharmacokinetic "modeling" of parenteral lidocaine therapy and the monitoring of lidocaine concentrations during and after open-heart surgery. Horning et al. (17) reported the use of EMIT assays in quantitating drugs in saliva. The application of such an approach to the pharmacokinetic "modeling" of lidocaine in the acute management of cardiac arrhythmias is very appealing. However, it must be realized that both physiological function and pharmacokinetics (e.g., serum/saliva lidocaine concentration ratios, saliva production and turnover, and lidocaine disposition) may lead to a different extrapolation of serum to saliva lidocaine concentrations between "normal" individuals and those experiencing cardiac arrhythmias.
The empirical use of lidocaine and procainamide during open-heart surgery has resulted in concentrations of >20 mg/liter fos both drugs. In such situations, accurate and rapid determinations are necessary. In order to respond, we have considered the development of a portable "satellite"
EMIT facility which would be readily available to the clinician. EMIT instrumentation and procedures are currently compatible with such a plan-a characteristic not shared by currently available chromatographic instrumentation and procedures.
The immunoassay reagents were supplied by the Syva Corp.
